Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population.

p53-binding protein 1 (P53BP1), a central transducer of DNA-damage signals to p53, is required for both intra-S-phase and G2-M checkpoints, suggesting that these two proteins may work together in the p53-mediated transcriptional activation and DNA damage-repair signaling pathways. Because the p53-binding region of 53BP1 maps to the C-terminal BRCT domains, which are homologous to those found in the breast cancer protein BRCA1, we hypothesized that genetic variation in P53BP1 and p53 may contribute to breast cancer predisposition. To test this hypothesis, we simultaneously genotyped single nucleotide polymorphisms of T-885G, Glu353Asp, and Gln1136Lys in P53BP1 and Arg72Pro in p53 in a case-control study of 404 breast cancer cases and 472 cancer-free controls. We found that the P53BP1 variant genotypes (alleles) of T-885G and Gln1136Lys were associated with a significantly increased risk of breast cancer among p53 Pro/Pro carriers (OR=2.36, 95% CI 1.16-4.83 for -885TG/GG; OR=2.24, 95% CI 1.15-4.37 for 1136Gln/Lys+Lys/Lys and OR=2.82, 95% CI 1.15-6.94 for >4 variant alleles of these 3 loci). In addition, the variant genotypes of above 3 loci of P53BP1 were significantly associated with elevated risk of progesterone receptor (PR) negative breast cancer, and the T-885G and Gln1136Lys with estrogen receptor (ER) negative breast cancer. Furthermore, we found a significant gene-gene interaction between P53BP1 Gln1136Lys and p53 Arg72Pro variants in relation to breast cancer, and the OR of interaction for the presence of both P53BP1 1136Gln/Lys+Lys/Lys and p53 72Arg/Pro+Pro/Pro genotypes was 1.93 (95% CI 1.06-3.52) (P=0.031 for interaction). These findings indicate that the SNPs in P53BP1 and p53 jointly contribute to breast cancer risk, particularly ER (-) or PR (-) breast cancer, and the p53 Arg72Pro polymorphism may serve as a risk modifier. Further functional studies are needed to confirm our findings.

[1]  T. Rauch,et al.  53BP1 is a Positive Regulator of the BRCA1 Promoter , 2005, Cell cycle.

[2]  A. Lambropoulos,et al.  The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. , 2005, Cancer letters.

[3]  P. Bugert,et al.  TP53-binding protein variants and breast cancer risk: a case-control study , 2005, Breast Cancer Research.

[4]  M. Papa,et al.  The R72P P53 mutation is associated with familial breast cancer in Jewish women , 2005, British Journal of Cancer.

[5]  Hongbing Shen,et al.  P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. , 2004, Oncology reports.

[6]  E. Guinó,et al.  A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA , 2004, Oncogene.

[7]  Jeffrey E. Lee,et al.  p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. , 2003, The Journal of investigative dermatology.

[8]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[9]  T. Eisen,et al.  TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. , 2003, Mutagenesis.

[10]  S. Elledge,et al.  Role for the BRCA1 C-terminal Repeats (BRCT) Protein 53BP1 in Maintaining Genomic Stability* , 2003, The Journal of Biological Chemistry.

[11]  Junjie Chen,et al.  p53 Binding Protein 53BP1 Is Required for DNA Damage Responses and Tumor Suppression in Mice , 2003, Molecular and Cellular Biology.

[12]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[13]  E. Imyanitov,et al.  Evidence against involvement of p53 polymorphism in breast cancer predisposition , 2003, International journal of cancer.

[14]  Jiri Bartek,et al.  53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer , 2002, Nature Cell Biology.

[15]  S. Elledge,et al.  53BP1, a Mediator of the DNA Damage Checkpoint , 2002, Science.

[16]  L. Serpell,et al.  Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor , 2002, The EMBO journal.

[17]  D. Spandidos,et al.  p53 codon 72 polymorphism and its association with bladder cancer. , 2002, Cancer letters.

[18]  M. Spitz,et al.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.

[19]  D. Livingston,et al.  Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. , 2002, Genes & development.

[20]  J. Glover,et al.  Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1 , 2001, Nature Structural Biology.

[21]  Shu Ye,et al.  PIRA PCR designer for restriction analysis of single nucleotide polymorphisms , 2001, Bioinform..

[22]  Junjie Chen,et al.  Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage–Signaling Pathways , 2001, The Journal of cell biology.

[23]  Y. Adachi,et al.  Phosphorylation and Rapid Relocalization of 53BP1 to Nuclear Foci upon DNA Damage , 2001, Molecular and Cellular Biology.

[24]  J. Morales,et al.  Negative Cell Cycle Regulation and DNA Damage-inducible Phosphorylation of the BRCT Protein 53BP1* , 2001, The Journal of Biological Chemistry.

[25]  T. Halazonetis,et al.  P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks , 2000, The Journal of cell biology.

[26]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[27]  T. Halazonetis,et al.  p 53 Binding Protein 1 ( 53 BP 1 ) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks , 2000 .

[28]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[29]  R. Gornall,et al.  p53 polymorphism and risk of cervical cancer , 1998, The Lancet.

[30]  M. Sternberg,et al.  Structure of an XRCC1 BRCT domain: a new protein–protein interaction module , 1998, The EMBO journal.

[31]  Bin Li,et al.  Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2* , 1998, The Journal of Biological Chemistry.

[32]  I. Jacobs,et al.  p53 codon 72 polymorphism and risk of cervical cancer in UK , 1998, The Lancet.

[33]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[34]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[35]  Peer Bork,et al.  A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Fields,et al.  Two cellular proteins that bind to wild-type but not mutant p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[39]  A. Deisseroth,et al.  Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. , 1992, Gene.